Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: A meta-analysis

Virology Journal

Volumn 11, Issue 1, 2014, Pages

  Liu, Fen ^a   Wang, Xiwei ^a   Wei, Fang ^a   Hu, Huaidong ^a   Zhang, Dazhi ^a   Hu, Peng ^a   Ren, Hong ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Adefovir dipivoxil; Combination; De novo; Entecavir; Lamivudine; Naive

Indexed keywords

ADEFOVIR DIPIVOXIL; CREATININE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

CHRONIC HEPATITIS B; COCHRANE LIBRARY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; EMBASE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MEDLINE; META ANALYSIS; MONOTHERAPY; REVIEW; SEROCONVERSION; SIDE EFFECT; SYSTEMATIC REVIEW; UREA NITROGEN BLOOD LEVEL; VIRUS RESISTANCE;

ADENINE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GUANINE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER FUNCTION TESTS; ORGANOPHOSPHONATES; TREATMENT OUTCOME;

EID: 84901660768     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-11-59     Document Type: Review

References (43)

1. Benefits and risks of nucleoside analog therapy for hepatitis B. Dienstag JL, Hepatology 2009 49 112 S121 10.1002/hep.22920 19399795
2. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. Fung J, Lai CL, Seto WK, Yuen MF, J Antimicrob Chemother 2011 66 2715 2725 10.1093/jac/dkr388 21965435
3. Antiviral resistance and hepatitis B therapy. Ghany MG, Doo EC, Hepatology 2009 49 174 S184 10.1002/hep.22900 19399794
4. A study on the treatment of chronic hepatitis B with YMDD mutation. Qiu YW, Jiang XH, Huang LH, Hu TH, Ding H, Jiang YM, Dai YX, Zhou M, Zhonghua Gan Zang Bing Za Zhi 2009 17 171 174 19335977
5. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L, Clin Infect Dis 2003 36 687 696 12627352 (Pubitemid 36337972)
6. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. Yao GB, Zhu M, Cui ZY, Wang BE, Yao JL, Zeng MD, J Dig Dis 2009 10 131 137 10.1111/j.1751-2980.2009. 00375.x 19426396
7. Management of treatment failure in chronic hepatitis B. Zoulim F, Locarnini S, J Hepatol 2012 56 112 S122 22300461
8. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, Cooksley G, Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA, Sollano JD, Suh DJ, Omata M, Hepatol Int 2012 6 531 561 10.1007/s12072-012-9365-4
9. Entecavir for the treatment of chronic hepatitis B infection. Shepherd J, Gospodarevskaya E, Frampton G, Cooper K, Health Technol Assess 2009 13 Suppl 3 31 36
10. Efficacy of entecavir in nucleoside-naive patients with hepatitis B e antigen-positive chronic hepatitis B. Zhang Q, Cheng ML, Liu Q, Mu M, Zhang YY, Liu BY, World Chin J Digestol 2009 17 2846 2849
11. Update in the management of chronic hepatitis B. Tujios SR, Lee WM, Curr Opin Gastroenterol 2013 29 250 256 10.1097/MOG.0b013e32835ff1e9 23519135
12. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E, Hepatology 2008 48 1460 1466 10.1002/hep.22524 18925641
13. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues. Patterson SJ, Angus PW, Curr Opin Organ Transplant 2009 14 225 230 10.1097/MOT.0b013e32832b1f32 19373086
14. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, J Gastroenterol Hepatol 2010 25 1374 1380 10.1111/j.1440-1746.2010. 06381.x 20659226
15. Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Chen EQ, Wang LC, Lei J, Xu L, Tang H, Virol J 2009 6 163 10.1186/1743-422X-6-163 19818142
16. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. Ijaz S, Arnold C, Dervisevic S, Mechurova J, Tatman N, Tedder RS, Naoumov NV, J Med Virol 2008 80 1160 1170 10.1002/jmv.21206 18461609 (Pubitemid 351705994)
17. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ, Hepatology 2007 45 307 313 10.1002/hep.21534 17256746 (Pubitemid 46374587)
18. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ, J Hepatol 2010 53 449 454 10.1016/j.jhep.2010.03.020 20646776
19. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy. Kim SS, Cho SW, Kim SO, Hong SP, Cheong JY, J Med Virol 2013 85 55 64 10.1002/jmv.23440 23096938
20. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, Brosgart CL, Woessner MA, Scott SA, Gray DF, Gardner SD, J Hepatol 2008 48 728 735 10.1016/j.jhep.2007.12.026 18329126
21. De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naive HBeAg-negative chronic hepatitis B patients. Wang LC, Chen EQ, Cao J, Liu L, Zheng L, Li DJ, Xu L, Lei XZ, Liu C, Tang H, Hepatol Int 2011 5 671 676 10.1007/s12072-010-9243-x 21484140
22. Efficacy and safety of lamivudine plus adefovir combination therapy and entecavir monotherapy for chronic hepatitis B patients. Yu JH, Shi JP, Wu J, Li XO, Guo JC, Xun YH, Zhao C, Jin J, Xu AF, Lou GQ, Zhonghua Gan Zang Bing Za Zhi 2011 19 88 92 21492508
23. Laboratory evaluation of three regimens of treatment of chronic hepatitis B: tenofovir, entecavir and combination of lamivudine and adefovir. Jayakumar R, Joshi YK, Singh S, J Lab Physicians 2012 4 10 16 10.4103/0974-2727.98664 22923916
24. De novo combination therapy with lamivudine and adefovir dipivoxii versus entecavir monotherapy for naive chronic hepatitis B patients with high viral loads. Zhang JC, Zhong Hua Lin Chuang Gan Ran Bing Xue Za Zhi 2012 3 142 144
25. Effect of entecavir and lamivudine combined with adefovir in treatment of e antigen-positive chronic hepatitis B. Wei W, Huang ZM, Zhong Hua Yi Yuan Gan Ran Bing Xue Za Zhi 2012 22 4335 4336
26. Nucleoside analogues for chronic hepatitis B. Wolters LMM, Niesters HGM, de Man RA, Eur J Gastroen Hepat 2001 13 1499 1506 10.1097/00042737-200112000- 00016 (Pubitemid 33151505)
27. Relationship between the expression of HBV DNA, HBV cccDNA in human ovary tissues and the HBV intrauterine infection. Yu MM, Gu XJ, Xia Y, Wang GJ, Kan NY, Wu KH, Zhonghua Liu Xing Bing Xue Za Zhi 2013 34 178 182 23751477
28. Quasispecies and pre-existing drug-resistant mutations of hepatitis B virus in patients with chronic hepatitis B. Kim do Y, Chang HY, Lim SM, Kim SU, Park JY, Kim JK, Lee KS, Han KH, Chon CY, Ahn SH, Gut Liver 2013 7 329 334 10.5009/gnl.2013.7.3.329 23710315
29. High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates. Neumann-Fraune M, Beggel B, Pfister H, Kaiser R, Verheyen J, J Med Virol 2013 85 775 779 10.1002/jmv.23530 23408582
30. Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. Yim HJ, Seo YS, Yoon EL, Kim CW, Lee CD, Park SH, Lee MS, Park CK, Chae HB, Kim MY, Baik SK, Kim YS, Kim JH, Lee JI, Lee JW, Hong SP, Um SH, Liver Int 2013 33 244 254 10.1111/liv.12036 23295056
31. Viroligic response to adefovir monotherapy and the risk of adefovir resistance. Sinn DH, Lee H, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH, World J Gastroenterol 2011 17 3526 3530 10.3748/wjg.v17.i30.3526 21941420
32. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trepo C, Zoulim F, J Hepatol 2008 48 747 755 10.1016/j.jhep.2008.01.027 18331765
33. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ, Antimicrob Agents Chemother 2004 48 3498 3507 10.1128/AAC.48.9.3498-3507.2004 15328117 (Pubitemid 39129351)
34. The high incidence of the emergence of entecavir-resistant mutants among patients infected with lamivudine-resistant hepatitis B virus. Nagasaki F, Niitsuma H, Ueno Y, Inoue J, Kogure T, Fukushima K, Shimosegawa T, Tohoku J Exp Med 2007 213 181 186 10.1620/tjem.213.181 17917412 (Pubitemid 47554877)
35. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL, Hepatology 2001 34 785 791 11584376 (Pubitemid 32928004)
36. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, Chao YC, Myers RP, Minuk GY, Jeffers L, Sievert W, Bzowej N, Harb G, Kaiser R, Qiao XJ, Brown NA, Ann Intern Med 2007 147 745 754 10.7326/0003-4819-147-11-200712040-00183 17909201 (Pubitemid 351664439)
37. Hepatitis B management. Das J, Clin Pharm 2010 2 17 21
38. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ, Hepatology 2009 49 1503 1514 10.1002/hep.22841 19280622
39. Viroligic response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients. Lu HY, Zhuang LW, Yu YY, Si CW, J Viral Hepat 2010 17 59 65
40. Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B. He Z, Wang J, Liu K, Huang H, Du Y, Lin Z, Cai M, Feng X, Clin Res Hepatol Gastroenterol 2012 36 592 597 10.1016/j.clinre.2012.05.012 23069315
41. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hui CK, Leung N, Shek TW, Yao H, Lee WK, Lai JY, Lai ST, Wong WM, Lai LS, Poon RT, Lo CM, Fan ST, Lau GK, Hepatology 2007 46 690 698 10.1002/hep.21758 17680649 (Pubitemid 47436114)
42. Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China. Wu B, Shen J, Cheng H, BMC Health Serv Res 2012 12 385 10.1186/1472-6963-12-385 23137013
43. Publication bias in meta-analysis: its causes and consequences. Thornton A, Lee P, J Clin Epidemiol 2000 53 207 216 10.1016/S0895-4356(99)00161-4 10729693 (Pubitemid 30151226)